×
Hero Background

Pericarditis Companies

ID: MRFR/Pharma/1315-CR
156 Pages
Rahul Gotadki
August 2019

Pericarditis is a medical condition characterized by inflammation of the pericardium, the thin sac-like membrane surrounding the heart. This inflammation can lead to chest pain, fever, and other symptoms, making it a critical condition that requires prompt diagnosis and treatment.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Pericarditis Market

Pericarditis Key Companies

 


Latest Pericarditis Companies Update:

R-Pharm International LLC announces positive Phase IIb results for CardiolRx: This investigational new drug for recurrent pericarditis demonstrates potential for long-term disease control and reduced risk of recurrence.


Cardiol Therapeutics acquires PerImmune to advance development of CardiolRx: This acquisition strengthens CardiolRx's clinical development program and expands its focus on treating recurrent pericarditis.


Abbott Laboratories partners with Inovio Pharmaceuticals to develop DNA vaccine for pericarditis: This collaboration aims to prevent pericarditis associated with viral infections or autoimmune diseases.


List of Pericarditis Key companies in the market

  • Pfizer Inc.

  • AstraZeneca Plc

  • Novartis International AG

  • Allergan plc.

  • and Merck & Co., Inc.

  • Bayer AG

  • Reckitt Benckiser Group Plc.

  • PerkinElmer, Inc.

  • FUJIFILM Holdings Corporation

  • Sanofi

  • Johnson & Johnson Services